IntrinsicIntrinsic
← All summaries

Cronos Group Inc.

CRON
Financials & Chart →

Business Summary

Cronos is an innovative global cannabinoid company focused on building disruptive intellectual property through cannabis research, technology, and product development, aiming to responsibly elevate the consumer experience and build an iconic brand portfolio . The company generates revenue primarily through the sale of cannabis flower and extracts, with a mix of recurring and transactional income derived from wholesale channels in Canada and international medical markets . Its primary customer segments include cannabis control authorities in Canadian provinces and territories, private-sector retailers in Saskatchewan, and pharmacies and third-party distributors in international medical markets .

Cronos operates through one consolidated segment, encompassing operations in Canada and Israel . In Canada, it operates Peace Naturals Project Inc. (Peace Naturals), a wholly owned license holder with production facilities at the Peace Naturals Campus in Stayner, Ontario . The company also consolidates the results of Cronos Growing Company Inc. (Cronos GrowCo), in which it maintains a 50% equity interest, and which serves as its principal source of cannabis . In Israel, Cronos operates under IMC-GAP, IMC-GMP, and IMC-GDP certifications for medical cannabis cultivation, production, distribution, and marketing . The company also distributes products in select international markets, including Germany, the United Kingdom, Australia, Switzerland, and Malta .

The company's brand portfolio includes Spinach®, PEACE NATURALS®, LIT™, and Lord Jones® . Spinach® is a mainstream adult-use cannabis brand offering dried flower, pre-rolls, vaporizers, and edibles in Canada . PEACE NATURALS® is a mainstream global medical brand distributed in Canada, Israel, Germany, Australia, Switzerland, and the UK, offering dried flower, pre-rolls, and tinctures . LIT™ is a value-driven medical cannabis brand providing dried flower in Germany, Israel, and the UK . Lord Jones® is a premium cannabis brand with products in pre-roll, vaporizer, concentrate, and edible categories in Canada and Israel .

For the fiscal year ended December 31, 2025, Cronos reported consolidated net revenue of $146.587 million , an increase of $28.972 million or 25% from $117.615 million in 2024. Cost of sales decreased by $8.536 million or 9% to $83.174 million from $91.710 million in 2024. Inventory write-down was $0.654 million in 2025, a decrease of $0.053 million or 7% from $0.707 million in 2024. Gross profit significantly increased by $37.561 million or 149% to $62.759 million from $25.198 million in 2024, resulting in a gross margin of 43% in 2025, up from 21% in 2024. Operating loss improved to $(17.395) million in 2025 from $(76.529) million in 2024. Net loss attributable to Cronos Group was $(9.447) million in 2025, compared to net income of $41.080 million in 2024. Diluted EPS was $(0.02) in 2025, compared to $0.11 in 2024. Cash and cash equivalents were $791.794 million and short-term investments were $40.000 million as of December 31, 2025, totaling $831.794 million . The company had no external debt financing as of December 31, 2025 .

The year-over-year revenue increase was primarily driven by higher cannabis flower sales in Israel and other countries, which carry no excise taxes, the inclusion of a full year of Cronos GrowCo sales, and higher cannabis extract sales in the Canadian market, partially offset by a decrease in Canadian cannabis flower sales due to supply constraints . Gross profit improvement was mainly due to lower inventory step-up from the Cronos GrowCo Transaction recognized into cost of sales, the consolidation of Cronos GrowCo, higher average sales prices from a mix shift to Israel and other countries, higher sales volumes, and production efficiencies . Operating expenses decreased by $21.573 million or 21% to $80.154 million in 2025 from $101.727 million in 2024, primarily due to lower salaries and benefits and lower expected credit loss allowances on loans receivable, partially offset by the consolidation of Cronos GrowCo and higher transaction costs .

Significant operational developments in 2025 included the acquisition agreement for CanAdelaar B.V., a licensed cannabis producer in the Netherlands, with closing subject to regulatory clearances . The expansion of the Cronos GrowCo facility was completed, with sales commencing in Fall 2025, and Cronos having an option to purchase up to 70% of its total production . The company sold its fermentation and manufacturing facility in Winnipeg, Manitoba (Cronos Fermentation Facility) for CAD $4.0 million on November 15, 2025 . Additionally, Cronos and Ginkgo Bioworks Holdings, Inc. mutually terminated their collaboration and license agreement on December 15, 2025, leading Cronos to exit fermentation-based cannabinoid manufacturing . Product launches included 10mg THC Fully Blasted SOURZ by Spinach® gummies with rare cannabinoids, new Spinach® 1g vapes, PEACE NATURALS® strain-specific oils and limited-edition premium flower series, and Lord Jones® Chocolate Fusions™ fudge brownie bite and Live Resin Caviar .

Business Outlook

Management believes that existing cash and cash equivalents and short-term investments will be sufficient to fund business operations and capital expenditures over the next twelve months, including continuing to fund the expansion of Cronos GrowCo's cultivation and processing facilities . As of December 31, 2025, the company had $791.794 million in cash and cash equivalents and $40.000 million in short-term investments .

A major growth area is the planned acquisition of CanAdelaar B.V., one of ten licensed cannabis producers in the Dutch Controlled Cannabis Supply Chain Experiment . The acquisition is for up-front consideration of €57.5 million , or approximately $67.5 million , subject to customary adjustments, with additional contingent consideration payable in cash based on 0.5x of CanAdelaar's normalized EBITDA in 2026 and 2027 . The up-front cash consideration is expected to be paid in the first half of 2026 and will be funded by available cash on hand . This acquisition is subject to closing conditions, including required regulatory clearances in the Netherlands, confirmations relating to CanAdelaar's licenses and Bibob review, accuracy of representations and warranties, and the absence of certain regulatory orders .

Another growth area is the expanded production capacity from the completed Cronos GrowCo facility, with sales commencing in Fall 2025 . Cronos has the option to purchase up to 70% of the total production from this expanded facility . This additional supply is anticipated to fuel growth internationally and within the domestic Canadian and wholesale markets in 2026 .

Operationally, the company expects to continue to incur significant costs and operating expenses as it implements initiatives to grow its business . The Realignment of functions and cost structure, changes to operations at the Peace Naturals Campus, and the Cronos GrowCo Transaction are recent operational and strategic initiatives . The company has exited fermentation-based cannabinoid manufacturing and no longer operates facilities leveraging intellectual property under the Ginkgo Collaboration Agreement .

Planned capital allocation includes continued investment in strategic partnerships and investees . The company has purchase obligations of $40.0 million as of December 31, 2025, with $27.6 million payable within 12 months, primarily for capital expenditures, computer software, agricultural supply services, and data analytics . Other purchase obligations for maintenance, internet, and telecommunication services total $2.1 million , with $1.2 million payable within 12 months . The GrowCo Credit Facility, with a closing balance of C$131.2 million 78 ($95.8 million ) as of December 31, 2025, is treated as an intercompany loan and eliminated upon consolidation .

Management explicitly flagged several structural headwinds and execution risks. The ongoing Middle East Conflict creates significant uncertainty for operations in Israel, potentially affecting sales, employee safety, facilities, and economic activity . The Anti-Dumping Investigation by the Israel Ministry of Economy and Industry, despite a court denial of a petition to impose a duty, still presents a risk of future import restrictions or duties, which could materially and adversely impact the business in Israel . The legal and regulatory framework governing U.S. hemp and hemp-derived products is complex and evolving, with recent legislation narrowing what qualifies as federally legal U.S. hemp and effectively prohibiting most intoxicating U.S. hemp products currently sold in the U.S. marketplace, with a ban scheduled for November 2026 . The Executive Order by President Trump directing the U.S. Attorney General to expedite marijuana rescheduling to Schedule III under the CSA has an uncertain impact, potentially leading to additional regulatory obligations or disproportionate benefits to competitors .

Risk Factors

The company faces material risks including geopolitical instability and armed conflict in the Middle East, which could disrupt Israeli operations, affect employee safety, damage facilities, and impair economic activity . The Anti-Dumping Investigation in Israel, despite a court denial of a petition to impose a duty, still poses a risk of future import restrictions or duties, which could materially and adversely impact the business . The legal and regulatory framework for U.S. hemp and hemp-derived products is complex and evolving, with recent legislation effectively prohibiting most intoxicating U.S. hemp products by November 2026 . The potential rescheduling of U.S. Schedule I cannabis to Schedule III under the CSA has an uncertain impact, possibly leading to additional regulatory obligations or disproportionate benefits to competitors . Operational risks include the reliance on Cronos GrowCo as the principal source of raw materials, with potential disruptions if supply needs are not met or if the supply agreement is terminated . Cybersecurity incidents, including data breaches or system malfunctions, could disrupt operations, harm reputation, and result in significant costs or penalties . The company is also exposed to fluctuations in foreign exchange rates, particularly between the U.S. dollar, Canadian dollar, and Israeli Shekel, which could lead to foreign exchange losses .

Management Priorities

Management's message to shareholders emphasizes a commitment to building disruptive intellectual property through cannabis research, technology, and product development, with a passion to responsibly elevate the consumer experience and build an iconic brand portfolio . The company's core strategic priorities include growing a portfolio of iconic brands, developing a diversified global sales and distribution network, establishing an efficient global supply chain, and creating and monetizing disruptive intellectual property . Management believes that existing cash and cash equivalents and short-term investments will be sufficient to fund business operations and capital expenditures over the next twelve months . The company is actively pursuing the acquisition of CanAdelaar B.V. for up-front consideration of €57.5 million , or approximately $67.5 million , with additional contingent consideration based on 0.5x of CanAdelaar's normalized EBITDA in 2026 and 2027 , expected to close in the first half of 2026 .

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 1, Business — Description of the Business — Overview
  2. [2] Item 1, Business — Core Business Model
  3. [3] Item 1, Business — Global Sales and Distribution - Principal Markets — Canadian Market and Distribution — Adult-Use; Item 1, Business — Global Sales and Distribution - Principal Markets — Canadian Market and Distribution — Medical Market; Item 1, Business — Global Sales and Distribution - Principal Markets — Markets and Distribution Outside of Canada — Israel
  4. [4] Item 1, Business — Business Segment
  5. [5] Item 1, Business — Business Segment
  6. [6] Item 1, Business — Business Segment
  7. [7] Item 1, Business — Business Segment
  8. [8] Item 1, Business — Operations Outside of Canada and Israel; Item 1, Business — Global Sales and Distribution - Principal Markets — Markets and Distribution Outside of Canada — United Kingdom; Item 1, Business — Global Sales and Distribution - Principal Markets — Markets and Distribution Outside of Canada — Other International Markets
  9. [9] Item 1, Business — Brand Portfolio
  10. [10] Item 1, Business — Brand Portfolio
  11. [11] Item 1, Business — Brand Portfolio
  12. [12] Item 1, Business — Brand Portfolio
  13. [13] Item 1, Business — Brand Portfolio
  14. [14] Item 7, MD&A — Consolidated Results of Operations - 2025 Compared to 2024 — Summary of select financial results
  15. [15] Item 7, MD&A — Consolidated Results of Operations - 2025 Compared to 2024 — Summary of select financial results
  16. [16] Item 7, MD&A — Consolidated Results of Operations - 2025 Compared to 2024 — Summary of select financial results
  17. [17] Item 7, MD&A — Consolidated Results of Operations - 2025 Compared to 2024 — Summary of select financial results
  18. [18] Item 7, MD&A — Consolidated Results of Operations - 2025 Compared to 2024 — Summary of select financial results
  19. [19] Item 7, MD&A — Consolidated Results of Operations - 2025 Compared to 2024 — Summary of select financial results
  20. [20] Item 7, MD&A — Consolidated Results of Operations - 2025 Compared to 2024 — Summary of select financial results
  21. [21] Item 7, MD&A — Consolidated Results of Operations - 2025 Compared to 2024 — Summary of select financial results
  22. [22] Item 7, MD&A — Consolidated Results of Operations - 2025 Compared to 2024 — Summary of select financial results
  23. [23] Item 7, MD&A — Consolidated Results of Operations - 2025 Compared to 2024 — Summary of select financial results
  24. [24] Item 7, MD&A — Consolidated Results of Operations - 2025 Compared to 2024 — Summary of select financial results
  25. [25] Item 7, MD&A — Consolidated Results of Operations - 2025 Compared to 2024 — Summary of select financial results
  26. [26] Item 7, MD&A — Consolidated Results of Operations - 2025 Compared to 2024 — Summary of select financial results
  27. [27] Item 7, MD&A — Consolidated Results of Operations - 2025 Compared to 2024 — Summary of select financial results
  28. [28] Item 7, MD&A — Consolidated Results of Operations - 2025 Compared to 2024 — Summary of select financial results
  29. [29] Item 7, MD&A — Consolidated Results of Operations - 2025 Compared to 2024 — Summary of select financial results
  30. [30] Item 7, MD&A — Consolidated Results of Operations - 2025 Compared to 2024 — Summary of select financial results
  31. [31] Item 7, MD&A — Consolidated Results of Operations - 2025 Compared to 2024 — Summary of select financial results
  32. [32] Item 7, MD&A — Consolidated Results of Operations - 2025 Compared to 2024 — Summary of select financial results
  33. [33] Item 7, MD&A — Consolidated Results of Operations - 2025 Compared to 2024 — Summary of select financial results
  34. [34] Item 7, MD&A — Consolidated Results of Operations - 2025 Compared to 2024 — Summary of select financial results
  35. [35] Item 7, MD&A — Consolidated Results of Operations - 2025 Compared to 2024 — Summary of select financial results
  36. [36] Item 8, Consolidated Statements of Net Income (Loss) and Comprehensive Income (Loss)
  37. [37] Item 8, Consolidated Statements of Net Income (Loss) and Comprehensive Income (Loss)
  38. [38] Item 7, MD&A — Liquidity and Capital Resources
  39. [39] Item 7, MD&A — Liquidity and Capital Resources
  40. [40] Item 7, MD&A — Liquidity and Capital Resources
  41. [41] Item 7, MD&A — Liquidity and Capital Resources
  42. [42] Item 7, MD&A — Consolidated Results of Operations - 2025 Compared to 2024 — Net revenue
  43. [43] Item 7, MD&A — Consolidated Results of Operations - 2025 Compared to 2024 — Gross profit
  44. [44] Item 7, MD&A — Consolidated Results of Operations - 2025 Compared to 2024 — Operating expenses
  45. [45] Item 7, MD&A — Consolidated Results of Operations - 2025 Compared to 2024 — Operating expenses
  46. [46] Item 7, MD&A — Consolidated Results of Operations - 2025 Compared to 2024 — Operating expenses
  47. [47] Item 7, MD&A — Consolidated Results of Operations - 2025 Compared to 2024 — Operating expenses
  48. [48] Item 7, MD&A — Consolidated Results of Operations - 2025 Compared to 2024 — Operating expenses — General and administrative
  49. [49] Item 7, MD&A — Recent Developments — CanAdelaar Acquisition
  50. [50] Item 7, MD&A — Recent Developments — Cronos GrowCo Expansion
  51. [51] Item 7, MD&A — Recent Developments — Sale of Cronos Fermentation Facility
  52. [52] Item 7, MD&A — Recent Developments — Sale of Cronos Fermentation Facility
  53. [53] Item 7, MD&A — Recent Developments — Termination of Ginkgo Collaboration Agreement
  54. [54] Item 7, MD&A — Recent Developments — Spinach®; Item 7, MD&A — Recent Developments — PEACE NATURALS®; Item 7, MD&A — Recent Developments — LIT™; Item 7, MD&A — Recent Developments — Lord Jones®
  55. [55] Item 7, MD&A — Liquidity and Capital Resources
  56. [56] Item 7, MD&A — Liquidity and Capital Resources
  57. [57] Item 7, MD&A — Liquidity and Capital Resources
  58. [58] Item 7, MD&A — Recent Developments — CanAdelaar Acquisition
  59. [59] Item 7, MD&A — Liquidity and Capital Resources — Cash requirements — Pending acquisition
  60. [60] Item 7, MD&A — Liquidity and Capital Resources — Cash requirements — Pending acquisition
  61. [61] Item 7, MD&A — Liquidity and Capital Resources — Cash requirements — Pending acquisition
  62. [62] Item 7, MD&A — Liquidity and Capital Resources — Cash requirements — Pending acquisition
  63. [63] Item 7, MD&A — Liquidity and Capital Resources — Cash requirements — Pending acquisition
  64. [64] Item 7, MD&A — Recent Developments — CanAdelaar Acquisition
  65. [65] Item 7, MD&A — Recent Developments — Cronos GrowCo Expansion
  66. [66] Item 7, MD&A — Recent Developments — Cronos GrowCo Expansion
  67. [67] Item 7, MD&A — Recent Developments — Cronos GrowCo Expansion
  68. [68] Item 1A, Risk Factors — Risks Relating to Our Growth Strategy — We may not be able to achieve or maintain profitability and may continue to incur losses in the future.
  69. [69] Item 1A, Risk Factors — Risks Relating to Our Growth Strategy — There can be no assurance that recent operational and strategic initiatives will have a beneficial impact on our business, financial condition and results of operations.
  70. [70] Item 7, MD&A — Recent Developments — Termination of Ginkgo Collaboration Agreement
  71. [71] Item 7, MD&A — Liquidity and Capital Resources — Cash requirements
  72. [72] Item 7, MD&A — Liquidity and Capital Resources — Cash requirements — Purchase obligations
  73. [73] Item 7, MD&A — Liquidity and Capital Resources — Cash requirements — Purchase obligations
  74. [74] Item 7, MD&A — Liquidity and Capital Resources — Cash requirements — Purchase obligations
  75. [75] Item 7, MD&A — Liquidity and Capital Resources — Cash requirements — Other purchase obligations
  76. [76] Item 7, MD&A — Liquidity and Capital Resources — Cash requirements — Other purchase obligations
  77. [77] Item 7, MD&A — Liquidity and Capital Resources — Cash requirements — Other purchase obligations [7, Item 7, MD&A — Liquidity and Capital Resources — Cash requirements — Cronos GrowCo Credit Facility
  78. [79] Item 7, MD&A — Liquidity and Capital Resources — Cash requirements — Cronos GrowCo Credit Facility
  79. [80] Item 7, MD&A — Liquidity and Capital Resources — Cash requirements — Cronos GrowCo Credit Facility
  80. [81] Item 1A, Risk Factors — Risks Relating to Operations in Israel — Conditions in Israel could materially and adversely affect our business, financial condition, and results of operations.
  81. [82] Item 1A, Risk Factors — Risks Relating to Operations in Israel — The imposition of an anti-dumping duty on our imports into Israel could have a material adverse effect on our business, financial condition and results of operations.
  82. [83] Item 1A, Risk Factors — Risks Relating to Regulation and Compliance — The legal and regulatory framework governing U.S. hemp and hemp-derived products is complex, evolving, and subject to significant uncertainty.
  83. [84] Item 1A, Risk Factors — Risks Relating to Regulation and Compliance — Any rescheduling of U.S. Schedule I cannabis to Schedule III would have an uncertain impact on our business.
  84. [85] Item 1A, Risk Factors — Risks Relating to Operations in Israel — Conditions in Israel could materially and adversely affect our business, financial condition, and results of operations.
  85. [86] Item 1A, Risk Factors — Risks Relating to Operations in Israel — The imposition of an anti-dumping duty on our imports into Israel could have a material adverse effect on our business, financial condition and results of operations.
  86. [87] Item 1A, Risk Factors — Risks Relating to Regulation and Compliance — The legal and regulatory framework governing U.S. hemp and hemp-derived products is complex, evolving, and subject to significant uncertainty.
  87. [88] Item 1A, Risk Factors — Risks Relating to Regulation and Compliance — Any rescheduling of U.S. Schedule I cannabis to Schedule III would have an uncertain impact on our business.
  88. [89] Item 1A, Risk Factors — Risks Relating to Production and Distribution of Products — We may be unable to obtain adequate supplies of raw materials in a timely manner and at commercially reasonable prices.
  89. [90] Item 1A, Risk Factors — Risks Relating to Production and Distribution of Products — We have in the past and may in the future experience unauthorized access to our information technology systems or other cybersecurity incidents, which could disrupt our operations and have a material adverse effect on our business.
  90. [91] Item 1A, Risk Factors — General Risk Factors — Our financial performance is subject to risks of foreign exchange rate fluctuation, which could result in foreign exchange losses.
  91. [92] Item 7, MD&A — Business Overview
  92. [93] Item 7, MD&A — Strategy
  93. [94] Item 7, MD&A — Liquidity and Capital Resources
  94. [95] Item 7, MD&A — Liquidity and Capital Resources — Cash requirements — Pending acquisition
  95. [96] Item 7, MD&A — Liquidity and Capital Resources — Cash requirements — Pending acquisition
  96. [97] Item 7, MD&A — Liquidity and Capital Resources — Cash requirements — Pending acquisition
  97. [98] Item 7, MD&A — Liquidity and Capital Resources — Cash requirements — Pending acquisition

Analysis on 5/22/2026